Blab Tech
Ultrahuman Launches Affordable M2 Live Continuous Glucose Monitor in the U.S.
Ultrahuman, a Bengaluru‑based health‑tech company, has announced the U.S. launch of its second‑generation continuous glucose monitor, the M2 Live. The new device uses Abbott’s Lingo sensor, a small, over‑the‑counter CGM that costs less than the company’s earlier M1 model. The launch comes with a range of pricing options, including a subscription that delivers two sensors each month for $99.
The M2 Live builds on the M1 platform that entered the market in 2021. While the M1 used Abbott’s earlier sensor, the M2 Live adopts the newer Lingo sensor, which is slightly more compact and is reported to be significantly cheaper. A single sensor lasts 14 days before replacement is required. The device continuously measures interstitial glucose levels and streams data via Bluetooth to the Ultrahuman mobile app. Users can view real‑time readings, trend graphs, and alerts for high or low values.
In addition to glucose data, the app integrates readings from Ultrahuman’s Ring Air smart ring, providing a broader view of metabolic health. The app includes a “Fuelling Score” that rates meals on a scale of 1 to 10 based on how the food is expected to affect blood sugar and workout readiness. It also flags irregularities and offers general tips for stabilizing glucose levels. An AI chatbot is available to answer user questions and suggest lifestyle adjustments.
Ultrahuman markets the M2 Live as a wellness product. The company states that it is not intended for people with diabetes who require insulin therapy. Instead, the device is aimed at non‑diabetic consumers interested in tracking metabolic responses to food, sleep, and exercise.
Pricing and availability are structured to accommodate different user preferences. The subscription model delivers two sensors per month for $99, which includes the sensor and the app service. Users who prefer not to subscribe can purchase sensors individually: a single sensor costs $129, a two‑pack is $129, and a year’s supply of 26 sensors is $1,229. The product is available through Ultrahuman’s website and is expected to ship in the U.S. within the coming weeks.
The move follows a broader trend of CGM adoption outside of clinical diabetes management. Continuous glucose monitors have long been used by people with type 1, type 2, or gestational diabetes, but recent years have seen increased use by athletes, people with prediabetes, and health‑conscious consumers. Abbott’s Lingo sensor is part of this shift, offering a consumer‑friendly, prescription‑free option that can be purchased over the counter.
Ultrahuman was founded in 2019 by Mohit Kumar and Vatsal Singhal, who previously co‑founded the food‑delivery startup Runnr. The company’s product lineup includes the Ring Air smart ring, the M1 CGM, an indoor home monitoring device, and blood‑testing services. The M2 Live is the latest addition to the company’s ecosystem, which aims to provide continuous, actionable health data.
The U.S. launch of the M2 Live represents a significant step for Ultrahuman, positioning it among a growing number of companies offering affordable, prescription‑free CGM solutions. The combination of a low‑cost sensor, a subscription model, and integration with existing health‑tracking devices could broaden the market for continuous glucose monitoring beyond traditional medical use.
As of now, the product is available for purchase in the United States, with no regulatory approval or prescription required. Users can download the Ultrahuman app to pair with the sensor and begin tracking glucose levels immediately. The company has not announced any further product releases or regulatory filings related to the M2 Live.
The M2 Live builds on the M1 platform that entered the market in 2021. While the M1 used Abbott’s earlier sensor, the M2 Live adopts the newer Lingo sensor, which is slightly more compact and is reported to be significantly cheaper. A single sensor lasts 14 days before replacement is required. The device continuously measures interstitial glucose levels and streams data via Bluetooth to the Ultrahuman mobile app. Users can view real‑time readings, trend graphs, and alerts for high or low values.
In addition to glucose data, the app integrates readings from Ultrahuman’s Ring Air smart ring, providing a broader view of metabolic health. The app includes a “Fuelling Score” that rates meals on a scale of 1 to 10 based on how the food is expected to affect blood sugar and workout readiness. It also flags irregularities and offers general tips for stabilizing glucose levels. An AI chatbot is available to answer user questions and suggest lifestyle adjustments.
Ultrahuman markets the M2 Live as a wellness product. The company states that it is not intended for people with diabetes who require insulin therapy. Instead, the device is aimed at non‑diabetic consumers interested in tracking metabolic responses to food, sleep, and exercise.
Pricing and availability are structured to accommodate different user preferences. The subscription model delivers two sensors per month for $99, which includes the sensor and the app service. Users who prefer not to subscribe can purchase sensors individually: a single sensor costs $129, a two‑pack is $129, and a year’s supply of 26 sensors is $1,229. The product is available through Ultrahuman’s website and is expected to ship in the U.S. within the coming weeks.
The move follows a broader trend of CGM adoption outside of clinical diabetes management. Continuous glucose monitors have long been used by people with type 1, type 2, or gestational diabetes, but recent years have seen increased use by athletes, people with prediabetes, and health‑conscious consumers. Abbott’s Lingo sensor is part of this shift, offering a consumer‑friendly, prescription‑free option that can be purchased over the counter.
Ultrahuman was founded in 2019 by Mohit Kumar and Vatsal Singhal, who previously co‑founded the food‑delivery startup Runnr. The company’s product lineup includes the Ring Air smart ring, the M1 CGM, an indoor home monitoring device, and blood‑testing services. The M2 Live is the latest addition to the company’s ecosystem, which aims to provide continuous, actionable health data.
The U.S. launch of the M2 Live represents a significant step for Ultrahuman, positioning it among a growing number of companies offering affordable, prescription‑free CGM solutions. The combination of a low‑cost sensor, a subscription model, and integration with existing health‑tracking devices could broaden the market for continuous glucose monitoring beyond traditional medical use.
As of now, the product is available for purchase in the United States, with no regulatory approval or prescription required. Users can download the Ultrahuman app to pair with the sensor and begin tracking glucose levels immediately. The company has not announced any further product releases or regulatory filings related to the M2 Live.
